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Abstract
Background: Despite decades of experience with praziquantel treatment in school-aged children (SAC) and adults,
we still face considerable knowledge gaps relevant to the successful treatment of preschool-aged children (PSAC).
This study aimed to assess the efficacy and safety of escalating praziquantel dosages in PSAC infected with
Schistosoma haematobium.
Methods: We conducted a randomised, dose-finding trial in PSAC (2–5 years) and as comparator a cohort of
SAC (6–15 years) infected with S. haematobium in Côte d’Ivoire. A total of 186 PSAC and 195 SAC were
randomly assigned to 20, 40 or 60 mg/kg praziquantel or placebo. The nature of the dose-response
relationship in terms of cure rate (CR) was the primary objective. Egg reduction rate (ERR) and tolerability were secondary
outcomes. CRs and ERRs were assessed using triplicate urine filtration over 3 consecutive days. Available-case analysis was
performed including all participants with primary endpoint data.
Results: A total of 170 PSAC and 174 SAC received treatment. Almost 90% of PSAC and three quarters of SAC were
lightly infected with S. haematobium. Follow-up data were available for 157 PSAC and 166 SAC. In PSAC, CRs of
praziquantel were 85.7% (30/35), 78.0% (32/41) and 68.3% (28/41) at 20, 40 and 60 mg/kg and 47.5% (19/40) for placebo.
In SAC, CRs were 10.8% for placebo (4/37), 55.6% for 20 mg/kg (25/45), 68.3% for 40 mg/kg (28/41) and 60.5% for 60 mg/
kg (26/43). ERRs based on geometric means ranged between 96.5% (60 mg/kg) and 98.3% (20 mg/kg) in PSAC and
between 97.6% (20 mg/kg and 60 mg/kg) and 98.6% (40 mg/kg) in SAC. Adverse events were mild and transient.
Conclusions: Praziquantel revealed dose-independent efficacy against light infections of S. haematobium. Over the dose
range tested, praziquantel displayed a ceiling effect with the highest response for 20 mg/kg in PSAC. In SAC maximum
efficacy was obtained with 40 mg/kg praziquantel. Further investigations are required in children with moderate to heavy
infections.
Trial registration: This trial is registered with International Standard Randomised Controlled Trial Number
ISRCTN15280205.
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Background
Schistosomiasis is a major public health problem with an
estimated 779 million people at risk of infection [1]. The
disease is caused by trematode worms of the genus Schis-
tosoma, where infection with Schistosoma japonicum and
S. mansoni causes mostly intestinal schistosomiasis, while
S. haematobium is responsible for genitourinary schisto-
somiasis [2–6]. Cumulative schistosome infections over
years, due to rapid reinfection, result in morbid sequelae,
including haematuria, nutritional deficiencies, anaemia,
hepatic peri-portal fibrosis and consequent portal hyper-
tension and delayed physical and cognitive development
[7–9]. Moreover, genitourinary schistosomiasis can lead to
obstruction and carcinomas of urogenital organs and im-
pairment to female reproductive health [6, 10]. To control
schistosomiasis morbidity, health authorities rely on mass
administration (preventive chemotherapy) of praziquantel
in school-aged children (SAC), the population most af-
fected [11–13]. In 2010, the World Health Organization
(WHO) endorsed the inclusion of preschool-aged children
(PSAC) in preventative chemotherapy programmes, since
there is increasing evidence that they are also affected by
schistosomiasis and could suffer from morbidity [14–17].
In the absence of an appropriate paediatric formulation,
broken or crushed praziquantel tablets are commonly
used in PSAC using the standard 40 mg/kg dose [18]. A
range of studies showed that this dose was well tolerated
and efficacious [15, 19, 20]. However, the heterogeneity of
methodology and reporting on praziquantel efficacy and
safety assessment make decision-making difficult [21].
In the paediatric population, growth and maturation of
organs are dynamic. Changes in body proportion and me-
tabolism occur throughout infancy and childhood that
affect how drugs are metabolised [22, 23]. Well-designed
paediatric drug trials are therefore warranted in order to
guide the proper usage of drug treatments to avoid under-
dosing, overdosing, ineffectiveness and safety problems.
We recently conducted a randomised, controlled
dose-finding study assessing the safety and efficacy of
praziquantel in PSAC and SAC infected with S. mansoni.
Considerable differences were observed between these
two age groups with regard to efficacy. For example,
while treatment of SAC with 40 or 60 mg/kg met the
WHO standards of clinical efficacy of ≥ 90% egg reduc-
tion rate (ERR) based on arithmetic mean (AM), none of
the doses administered could reach this threshold in
PSAC [24].
This study was designed to support the ongoing efforts
to successfully control schistosome infections in PSAC
by assessing the efficacy and safety of escalating prazi-
quantel dosages in PSAC compared to SAC infected
with S. haematobium. The clinical evidence for prazi-
quantel obtained for both S. haematobium and S. man-
soni in PSAC will facilitate the clinical decision-making
process, resulting in successful control of schistosome
infection and disease.
Methods
Study design and participants
We conducted a randomised, parallel-group, single-blind,
placebo-controlled, dose-ranging trial between November
2015 and February 2016. PSAC (aged 2–5 years) and SAC
(6–15 years) were surveyed in five villages of the health
district of Adzopé, southern Côte d’Ivoire. In total, 740
PSAC and 444 SAC were registered during the census and
were invited to participate in the study.
Randomisation and masking
Eligibility of children was based on the presence of
S. haematobium eggs in their urine. In addition, a clinical
examination and an oral medical history by active ques-
tioning were implemented in order to exclude children
with abnormal medical conditions (i.e. clinical malaria or
hepato-splenic schistosomiasis) or those who received an
antimalarial or anthelmintic drug in the past 4 weeks.
S. haematobium egg-positive PSAC and SAC, eligible
for the study, were stratified according to baseline infec-
tion intensity into light (< 50 eggs/10 mL of urine) or
heavy (≥ 50 eggs/10 mL of urine) infection intensities
[25]. Children were then randomly assigned to placebo
or 20, 40 or 60 mg/kg praziquantel treatment arms using
computer-generated stratified block randomisation codes
provided by an independent statistician based on the
aforementioned infection intensity (block size of 8). Only
the investigator dealing with drug administration was
aware of the treatment assignments. The physician and
laboratory technicians were blinded to the treatment.
SAC might have recognised the treatment dose due to
the number of tablets administered; however, the crush-
ing of tablets for PSAC was prepared in advance. Mask-
ing was maintained throughout the trial. Randomisation
codes were released after the database was unlocked.
Field and laboratory procedures
During the baseline survey, three urine samples over 3
consecutive days and a single stool sample from the first
collection day were collected between 10:00 and
14:00 am from each participating child. Urine and stool
samples were transferred to a nearby laboratory in
Azaguié town and examined on the day of collection.
S. haematobium was detected using the urine filtra-
tion method (syringe filtration of 10 mL of urine followed
by microscopic examination of the filter) [26]. A subse-
quent independent quality control of sample results (ap-
proximately 10%) was conducted. If a difference in
presence/absence of S. haematobium eggs was observed
or egg counts exceeded +/−10 eggs for light infections or
+/−20 eggs for heavy infections, all the slides were read
Coulibaly et al. BMC Medicine  (2018) 16:81 Page 2 of 10
once again by the senior technician. S. mansoni infection
was assessed through duplicate Kato-Katz thick smears
(standard template of 41.7 mg) [27]. Eggs of
soil-transmitted helminths, i.e. Ascaris lumbricoides,
hookworm and Trichuris trichiura, were also assessed and
recorded for each parasite species separately. Moreover,
finger prick blood samples were taken to assess Plasmo-
dium infections and haemoglobin amount using, respect-
ively, thick and thin blood smears [24] and a calibrated
HemoCue device (HemoCue 301 system, HemoCue,
Ängelholm, Sweden).
To assess treatment efficacy, another three urine samples
and a single stool sample were collected between 21 and
25 days post-treatment and subjected to the same diagnos-
tic approaches applied at baseline. At the end of the study,
all children enrolled in the study were offered albendazole
(400 mg) and praziquantel (40 mg/kg) for the treatment of
helminth infections according to local guidelines.
Treatment
Prior to treatment, each child received breakfast. In both
study groups (SAC and PSAC), treatment was done
based on the child’s body weight (graduated increments
of 0.1 kg). Praziquantel (600 mg Cesol®) (used in
quarter-tablet increments) and placebo were obtained
from Merck KGaA, Darmstadt, Germany and Fagron,
Barsbüttel, Germany, respectively. For PSAC, tablets
were crushed using a mortar and pestle and dissolved in
a small volume of syrup-flavoured water to mask the
taste. SAC and the mothers/guardians of PSAC were
interviewed 3, 24, 48 and 72 h after treatment for ad-
verse events and the intensities graded by the study
physician as mild, moderate, severe or intolerable [24].
Outcomes and sample size determination
The cure rate (CR) (primary outcome) was expressed as
the proportion of children positive for S. haematobium
eggs at baseline survey who became negative at
follow-up. The secondary outcomes were ERR and the
safety of different doses of praziquantel.
Simulations showed that with 40 children enrolled per
treatment arm (0, 20, 40 and 60 mg/kg), the dose-response
prediction model should have a median precision—defined
as one half length of the 95% confidence interval (CI)—of
10% points, assuming associated cure rates of 2.5%, 50%,
75% [28] and 90%.
Statistical analysis
All data were first double entered into an Excel spread-
sheet, then transferred into Epi Info version 3.5.2
(Centers for Disease Control and Prevention, Atlanta,
GA, USA) and cross-checked. R version 3.4.0 was used
for all statistical analyses. Available-case analysis was
implemented including all treated participants (regard-
less of whether they could swallow the drug or not or
were wrongly dosed) who had at least one urine sample
examined with the urine filtration method at follow-up
and were not excluded due to a medical condition.
In order to calculate ERR, the AM and geometric
mean (GM) of eggs per 10 mL of urine before and after
treatment were assessed. Geometric mean egg counts
were calculated as follows: e1/n ∑ log(x + 1) -1, and the
corresponding ERR ([1 – geometric mean egg output
after treatment/geometric mean egg output at
baseline] × 100) was assessed. A bootstrap resampling
method with 5000 replicates was used to estimate 95%
CIs for ERRs.
Emax models using the DoseFinding package (version
0∙9–14) of the statistical software environment R (v3.3.0)
were implemented to predict the dose-response curves
in terms of CRs and ERRs. Logistic regression was used
to predict CR by infection intensity at baseline.
Results
Study flow and baseline characteristics
Overall, 1184 children were invited to participate in the
study (Fig. 1). At baseline, 628 PSAC and 356 SAC were
screened for S. haematobium infection. Of these, 186
(29.6%) PSAC and 195 (45.7%) SAC had a detectable
S. haematobium infection and were randomised for
treatment. On the treatment day, 16 PSAC and 21 SAC
were absent. PSAC received 20 mg/kg (n = 40), 40 mg/kg
(n = 44) or 60 mg/kg (n = 44) praziquantel or placebo
(n = 42). SAC were likewise allocated to 20 mg/kg (n =
46), 40 mg/kg (n = 46) or 60 mg/kg praziquantel (n = 44)
or placebo (n = 38). Two PSAC and one SAC were not
able to swallow the drug. One PSAC and one SAC were
wrongly dosed (62.5 mg/kg instead of 40 mg/kg and
75 mg/kg instead of 40 mg/kg, respectively).
At follow-up, data were available for 157 PSAC and
166 SAC. One PSAC and 12 SAC provided only two
urine samples, while one SAC provided only one urine
sample.
The median age, weight, height and sex of PSAC
and SAC were balanced among the treatment groups
(Table 1). Three quarters of PSAC and SAC were
lightly infected with S. haematobium. No infection
with A. lumbricoides, T. trichiura or hookworm was
recorded. Co-infections among S. haematobium-infected
children with S. mansoni and P. falciparum were very low
(less than 9%) in PSAC and SAC. Median haemoglobin
values ranged between 10.5 and 11.0 g/dL in PSAC and
between 11.0 and 11.7 g/dL in SAC.
Efficacy of praziquantel
The nature of the dose response based on CRs is depicted
in Fig. 2. Praziquantel revealed dose-independent efficacy
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with the highest cure rates observed at 20 and 40 mg/
kg in PSAC and SAC, respectively. The Emax model
based on actual doses on the per protocol population is
presented in Additional file 1: Figure S1 and shows a
similar trend. Additional file 1: Figure S2 presents the
predicted probability of being cured by baseline infec-
tion intensity. For all treatments, including placebo,
there was a high probability of being cured at low infec-
tion intensities.
CRs in PSAC for 20 mg/kg, 40 mg/kg and 60 mg/kg
were 85.7 (95% CI 69.7–95.2), 78.0% (95% CI 62.4–89.4)
and 68.3% (95% CI 51.9–81.9), respectively, whereas in
SAC the respective CRs were 55.6% (95% CI 40.0–70.4),
68.3% (95% CI 51.9–81.9) and 60.5% (95% CI 44.4–75.0).
In the placebo groups, S. haematobium eggs were not
detected in the urine samples of 47.5% (19/40) and
10.8% (4/37) in PSAC and SAC, respectively (Table 2).
Imputation of missing data with treatment failure or
success in the intention-to-treat analysis did not change
the observed outcomes (Additional file 1: Table S1).
ERRs are summarized in Table 2 and depicted in
Fig. 3. ERRs in PSAC were 98.3% for 20 mg/kg, 97.6%
for 40 mg/kg and 96.5% for 60 mg/kg. In SAC ERRs of
97.6%, 98.6% and 97.6% were observed with increasing
dosages. ERRs based on AMs had similar profiles to
those based on GMs and are presented in Table 2.
Table 2 also presents an exploratory subgroup analysis
on CRs according to S. haematobium infection inten-
sity. The CR in PSAC ranged from 73.0% (60 mg/kg)
to 87.9% (20 mg/kg) in light infections and from
25.0% (60 mg/kg) to 66.7% (40 mg/kg) in heavy infec-
tions. In SAC, CRs were 70.6% (20 mg/kg) to 78.8%
(40 mg/kg) for light S. haematobium infections and
between 9.1% (20 mg/kg) and 27.3% (60 mg/kg) for
heavy infections.
Safety of praziquantel
Adverse events data were available for 168 PSAC and
173 SAC (Table 3). In both groups, more children re-
ported signs and symptoms at pre-treatment compared
to 3 and 24 h post-treatment. No serious adverse events
were reported. Overall, adverse events were mild with
fewer adverse events observed at 3 h post-treatment
compared to pre-treatment in PSAC (52 episodes versus
88 episodes) and in SAC (88 episodes versus 92 epi-
sodes), respectively. Mild events mainly included fever,
Fig. 1 Trial profile
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headache, nausea, diarrhoea, vomiting, dizziness and
stomach ache. Few moderate cases were reported at
3 h after treatment in PSAC (only one with moderate
diarrhoea) and in SAC (n = 12). At 24 h
post-treatment, 25 (14.9%) and 47 (27.2%) adverse
events were recorded in PSAC and SAC, respectively.
For both age groups the number of adverse events was
similar among the three praziquantel treatment arms,
with fewer adverse events observed in the
placebo-treated groups. The most common adverse
events in PSAC and SAC 24 h post-treatment were
diarrhoea (4.8 and 3.5%), stomach ache (3.6 and 9.8%),
fever (6.0 and 13.3%), headache (3.0 and 15.6%) and
nausea (2.4 and 6.9%).
Discussion
Over the past decade, preventive chemotherapy pro-
grammes for the control of schistosomiasis targeting
SAC have scaled up across many countries in tropical
and subtropical areas. Great progress has been made in
decreasing the burden of this disease [29–31]. However,
recent modelling and health economic studies found
that expanded community-wide preventive chemother-
apy that includes adolescents, adults and PSAC would
better reduce the overall disease burden, rates of trans-
mission and reinfection [32].
It was recommended in 2010 that PSAC should be in-
cluded in preventive chemotherapy programmes [33]
using an adequate dose, though this age group is still lack-
ing a suitable formulation. A paediatric formulation of
praziquantel (small, orally dispersible tablets) is under de-
velopment (https://www.pediatricpraziquantelconsortium
.org/node/28), but it will take several more years until the
drug is marketed and available to all PSAC. To be able to
treat preschoolers safely and effectively, we studied as-
cending doses of praziquantel in PSAC and SAC infected
Table 1 Baseline characteristics
Preschool-aged children (PSAC) School-aged children (SAC)
Treatment arm Treatment arm
Characteristics Placebo 20 mg/kg 40 mg/kg 60 mg/kg Placebo 20 mg/kg 40 mg/kg 60 mg/kg
42 40 44 44 38 46 46 44
Female N (%) 23 (54.8) 21 (52.5) 20 (45.5) 27 (61.4) 23 (60.5) 25 (54.3) 25 (54.3) 25 (56.8)
Age, years; median 4 4 4 4 9 8 8 9
[IQR] [2–5] [2–5] [2–5] [2–5] [6–13] [6–13] [6–14] [6–13]
Weight, kg; median 15 15 15 15 22 22 24 22
[IQR] [10–21] [11–19] [11–19] [11–18] [18–35] [18–33] [18–38] [18–40]
Height, cm; median 97 98 101 100 125 125 125 124
[IQR] [80–117] [83–115] [84–116] [83–114] [109–141] [114–139] [113–149] [112–150]
Haemoglobin (g/dL); median 10.5 11.0 10.9 10.9 11.4 11.2 11.7 11.6
[IQR] [9.1–13.2] [9.1–12.8] [8.8–12.5] [8.5–12.9] [9.7–13.7] [9.9–12.4] [9.7–12.8] [10.1–13.5]
Infection intensity N (%)
Light 36 (85.7) 38 (95.0) 38 (86.4) 40 (90.9) 27 (71.1) 35 (76.1) 36 (78.3) 33 (75.0)
Heavy 6 (14.3) 2 (5.0) 6 (13.6) 4 (9.1) 11 (28.9) 11 (23.9) 10 (21.7) 11 (25.0)
Co-infections N (%)
S. mansoni 0 (0.0) 0 (0.0) 1 (2.3) 1 (2.3) 0 (0.0) 1 (2.2) 1 (2.2) 0 (0.0)
Plasmodium falciparum 1 (2.4) 0 (0.0) 1 (2.3) 0 (0.0) 1 (2.6) 4 (8.7) 2 (4.3) 3 (6.8)
(based on thin/thick smear)
IQR interquartile range
Fig. 2 Cure rates in PSAC (blue lines) and SAC (red lines). Circles show
observed cure rates with 95% CIs (vertical lines). Numbers in the circles
show geometric mean infection intensities at baseline (BL). Dashed
lines represent the estimated dose-response curve and corresponding
95% CIs predicted by the Emax models. Geometric mean of infection
intensity was the mean of eggs filtered from 10 mL of urine
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with S. haematobium. Our results build on an earlier
dose-finding study in S. mansoni-infected children [24].
Several findings of our study are worth highlighting.
First, the highest overall CRs among PSAC (85.7%) and
SAC (68.3%) were obtained with 20 mg/kg and 40 mg/
kg praziquantel, respectively and not with the highest
dose administered, 60 mg/kg. For both age groups, CRs
revealed even a slight inverse dose-rate effect. Similarly,
ERRs increased very fast up to 98% and did not increase
further regardless of the praziquantel dose administered.
Interestingly, 60 mg/kg praziquantel also showed lower
CRs in PSAC with moderate/high S. haematobium infec-
tion intensities compared to the two lower doses. For ex-
ample, the CR in PSAC characterised by heavy infection
intensities treated with 60 mg/kg praziquantel was as
low as 25%. However, only a handful of PSAC suffered
from moderate and high infection intensities; hence, no
clear picture can be drawn for this age group. In SAC
similar CRs were observed in children harbouring heavy
infection intensities treated with 40 and 60 mg/kg. In
summary, a high dose of praziquantel seems to have no
additional benefit in the treatment of S. haematobium
infections. This result is in contrast with our recent
Table 2 Available-case analysis of cure and egg reduction rates of 20, 40 and 60 mg/kg praziquantel versus placebo against urogenital
schistosomiasis in PSAC and SAC based on the urine filtration method
Preschool-aged children (PSAC) School-aged children (SAC)
Placebo 20 mg/kg 40 mg/kg 60 mg/kg Placebo 20 mg/kg 40 mg/kg 60 mg/kg
Infected children before treatment (N) 40 35 41 41 37 45 41 43
Actual dose administered (range; mg/kg) – 13.6–25 34.6–62.5a 50–70 – 16.7–23.7 36.4–75b 56.3–65.6
Cured children after treatment N (%) 19 (47.5) 30 (85.7) 32 (78.0) 28 (68.3) 4 (10.8) 25 (55.6) 28 (68.3) 26 (60.5)
95% CI 32.5–63.9 69.7–95.2 62.4–89.4 51.9–81.9 3.0–25.4 40.0–70.4 51.9–81.9 44.4–75.0
Cured children according to sex
Male 6 (31.6) 14 (46.7) 19 (59.4) 10 (35.7) 1 (25.0) 9 (36.0) 13 (46.4) 9 (34.6)
95% CI 12.5–56.6 28.3–65.7 40.6–76.3 18.6–55.9 0.6–80.6 18.0–57.5 27.5–66.1 17.2–55.7
Female 13 (68.4) 16 (53.3) 13 (40.6) 18 (64.3) 3 (75.0) 16 (64.0) 15 (53.6) 17 (65.4)
95% CI 43.4–87.4 34.3–71.7 23.7–59.4 44.1–81.4 19.4–99.4 42.5–82.0 33.9–72.5 44.3–82.8
Cured children with light infection 19/40 (47.5) 29/33 (87.9) 28/35 (80.0) 27/37 (73.0) 4/26 (15.4) 24/34 (70.6) 26/33 (78.8) 23/32 (71.9)
Cured children with heavy infections (%) 0/6 (0) 1/2 (50.0) 4/6 (66.7) 1/4 (25.0) 0/11 (0.0) 1/11 (9.1) 2/8 (25.0) 3/11 (27.3)
Geometric mean eggs/10 mL of urine
Before treatment 7.8 7.5 8.4 8.3 31.5 21.6 16.6 17.2
After treatment 2.4 0.1 0.2 0.3 13.1 0.5 0.2 0.4
Egg reduction rate 68.9 98.3 97.6 96.5 58.5 97.6 98.6 97.6
(95% CI) 46.6–83.6 95.4–99.8 94.9–99.2 93.1–98.7 38.7–71.4 96.4–98.6 97.7–99.3 95.3–98.9
Arithmetic mean eggs/10 mL of urine
Before treatment 22.7 14.3 21.7 16.9 94.4 89.5 31.0 34.4
After treatment 11.5 0.3 0.4 0.9 49.0 1.2 0.4 1.0
Egg reduction rate 49.5 97.8 98.2 94.5 46.9 98.7 98.8 97.0
(95% CI) 0.2–77.3 93.6–99.9 96.1–99.5 85.7–99.1 36.4–77.6 96.7–99.3 97.7–99.5 92.9–99.2
aRange 34.6–44.1 excluding the wrongly dosed child
bRange 36.4–42.9 excluding the wrongly dosed child
Fig. 3 Egg reduction rates in PSAC (blue lines) and SAC (red lines).
Diamonds show observed cure rates with 95% CIs (vertical lines).
Dashed lines represent the estimated dose-response curve and
corresponding 95% CI predicted by the Emax model
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study, where we reported that in SAC infected with S.
mansoni, CRs increased with higher doses of praziquan-
tel [24], while only moderate CRs were observed in
PSAC at all doses administered.
Overall higher CRs were observed in PSAC (68–86%)
when compared to SAC (56–68%), which mirrors a re-
cent meta-analysis by Zwang et al., where 40 mg/kg
praziquantel cured 87.3% of S. haematobium-infected
PSAC compared to 71.4% of SAC [34]. Nonetheless, our
finding can most likely be explained with the lower in-
fection intensities present in PSAC, as CRs in children
characterised by heavy infection intensities were low.
Hence, our results confirm the relationship between CRs
and infection intensity observed in previous studies [35,
36]. Overall, the results emphasise the need for rigorous
treatment programmes in settings with heavy infection
Table 3 Main type of clinical symptoms (number and percentage) before treatment and adverse events 3 and 24 h after praziquantel
administration in Schistosoma haematobium-infected preschool-aged children (n = 168) and school-aged children (n = 173)
Preschool-aged children (PSAC)a School-aged children (SAC)b
Symptoms Placebo 20 mg/kg 40 mg/kg 60 mg/kg Overall Placebo 20 mg/kg 40 mg/kg 60 mg/kg Overall
(n = 41) (n = 40) (n = 44) (n = 43) (n = 168) (n = 38) (n = 45) (n = 46) (n = 44) (n = 173)
Before treatment
Moderate 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Mild 24 (58.5) 19 (47.5) 26 (59.1) 19 (44.2) 88 (52.4) 20 (52.6) 26 (57.8) 25 (54.3) 21 (47.7) 92 (53.2)
None 17 (41.5) 21 (52.5) 18 (40.9) 24 (55.8) 80 (47.6) 18 (47.4) 19 (42.2) 21 (45.7) 23 (52.3) 81 (46.8)
Fever 6 (14.1) 3 (7.5) 7 (15.9) 5 (11.6) 21 (12.5) 5 (13.2) 7 (15.6) 5 (10.9) 6 (13.6) 23 (13.3)
Headache 8 (19.5) 6 (15.0) 13 (29.5) 10 (23.3) 37 (22.0) 3 (7.9) 7 (15.6) 10 (21.7) 7 (15.9) 27 (15.6)
Nausea 3 (7.3) 4 (10.0) 3 (6.8) 1 (2.3) 11 (6.5) 2 (5.3) 1 (2.2) 4 (8.7) 5 (11.4) 12 (6.9)
Vomiting 1 (2.4) 1 (2.5) 1 (2.3) 2 (4.7) 5 (3.0) 0 (0.0) 0 (0.0) 1 (2.2) 0 (0.0) 1 (0.6)
Diarrhoea 4 (9.6) 4 (10.0) 4 (9.1) 5 (11.6) 17 (10.1) 0 (0.0) 1 (2.2) 3 (6.5) 2 (4.5) 6 (3.5)
Dizziness 2 (4.9) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Stomach ache 2 (4.9) 5 (12.5) 8 (18.2) 4 (9.3) 19 (11.3) 1 (2.6) 6 (13.3) 6 (13.0) 4 (9.1) 17 (9.8)
3 h post-treatment
Moderate 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.3) 1 (0.6) 1 (2.6) 2 (4.4) 4 (8.7) 5 (11.4) 12 (6.9)
Mild 6 (14.6) 8 (20.0) 15 (34.1) 23 (53.5) 52 (31.0) 18 (47.4) 23 (51.1) 21 (45.7) 26 (59.1) 88 (50.9)
None 35 (85.4) 32 (80.0) 29 (65.9) 19 (44.2) 115 (68.5) 19 (50.0) 20 (44.4) 21 (45.7) 13 (29.5) 73 (42.2)
Fever 3 (7.3) 3 (7.5) 2 (4.5) 4 (9.3) 12 (7.1) 6 (15.8) 4 (8.9) 8 (17.4) 12 (27.3) 30 (17.3)
Headache 1 (2.4) 2 (5.0) 1 (2.3) 7 (16.3) 11 (6.5) 8 (21.1) 10 (22.2) 6 (13.0) 6 (13.6) 30 (17.3)
Nausea 1 (2.4) 1 (2.5) 4 (9.1) 5 (11.6) 11 (6.5) 4 (10.5) 3 (6.7) 9 (19.6) 14 (31.8) 30 (17.3)
Vomiting 0 (0.0) 1 (2.5) 3 (6.8) 9 (20.9) 13 (7.7) 1 (2.6) 3 (6.7) 8 (17.4) 10 (22.7) 22 (12.7)
Diarrhoea 0 (0.0) 1 (2.5) 1 (2.3) 3 (7.0) 5 (3.0) 3 (7.9) 3 (6.7) 2 (4.3) 0 (0.0) 8 (4.6)
Dizziness 1 (2.4) 1 (2.5) 2 (4.5) 4 (9.3) 8 (4.8) 5 (13.2) 4 (8.9) 8 (17.4) 5 (11.4) 22 (12.7)
Stomach ache 3 (7.3) 4 (10.0) 4 (9.1) 2 (4.7) 13 (7.7) 5 (13.2) 11 (24.4) 9 (19.6) 12 (27.3) 37 (21.4)
24 h post-treatment
Moderate 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Mild 4 (9.6) 7 (17.5) 8 (18.2) 6 (14.0) 25 (14.9) 12 (31.6) 12 (26.7) 12 (26.1) 11 (25.0) 47 (27.2)
None 37 (90.2) 33 (82.5) 36 (81.8) 37 (86.0) 143 (85.1) 26 (68.4) 33 (73.3) 34 (73.9) 33 (75.0) 126 (72.8)
Fever 2 (4.9) 4 (10.0) 2 (4.5) 2 (4.7) 10 (6.0) 5 (13.2) 7 (15.6) 5 (10.9) 6 (13.6) 23 (13.3)
Headache 1 (2.4) 1 (2.5) 1 (2.3) 2 (4.7) 5 (3.0) 3 (7.9) 7 (15.6) 10 (21.7) 7 (15.9) 27 (15.6)
Nausea 1 (2.4) 0 (0.0) 0 (0.0) 3 (7.0) 4 (2.4) 2 (5.3) 1 (2.2) 4 (8.7) 5 (11.4) 12 (6.9)
Vomiting 0 (0.0) 0 (0.0) 0 (0.0) 3 (7.0) 3 (1.8) 0 (0.0) 0 (0.0) 1 (2.2) 0 (0.0) 1 (0.6)
Diarrhoea 1 (2.4) 2 (5.0) 5 (11.4) 0 (0.0) 8 (4.8) 0 (0.0) 1 (2.2) 3 (6.5) 2 (4.5) 6 (3.5)
Dizziness 1 (2.4) 0 (0.0) 0 (0.0) 1 (2.3) 1 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Stomach ache 2 (4.9) 0 (0.0) 2 (4.5) 2 (4.7) 6 (3.6) 1 (2.6) 6 (13.3) 6 (13.0) 4 (9.1) 17 (9.8)
a2 children were absent (placebo (n = 1) and 60 mg/kg (n = 1)) following treatment and were not assessed for adverse events
b1 child was absent (20 mg/kg treatment arm) following treatment and was not assessed for adverse events
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of S. haematobium, since reductions in egg output sig-
nificantly correlated with decreased morbidity [37, 38].
No dose-response relationship was observed for ERRs
in both age groups above 20 mg/kg. This finding is in
line with an earlier meta-analysis by Zwang et al. [34]
which found no significant relationship for dose and
ERR for any of the Schistosoma species. However, our
dose-finding study in S. mansoni-infected children
showed that higher ERRs (based on GMs) were observed
in children treated with 40 and 60 mg/kg compared to
20 mg/kg [24]. Recent WHO Standard Operating Proce-
dures have set a threshold of a 90% ERR based on AM
for clinical efficacy and recommend that control pro-
grammes should investigate drug performance in popu-
lations where the ERR is lower [39]. Regardless of age
group and whether GM or AM was used to determine
ERRs, we found that all praziquantel doses used against
S. haematobium, in contrast to preschoolers infected
with S. mansoni [24], yielded ERRs above 90%. Despite
the excellent efficacy of 20 mg/kg of praziquantel against
light S. haematobium infections in this study, the use of
two different doses, namely 20 mg/kg for S. haemato-
bium and 40 mg/kg for S. mansoni in settings where
Schistosoma species are overlapping, would raise logis-
tical and operational challenges since control pro-
grammes are acting at large-scale levels such as district
or country levels. Therefore, rigorous cost-effectiveness
studies need to be implemented before a change of treat-
ment guidelines could be considered. However, at a
point-of-care level, using a test-and-treat approach,
20 mg/kg and 40 mg/kg could be recommended to treat
PSAC for S. haematobium and S. mansoni infections,
respectively.
In PSAC we observed a high CR in the placebo arm
similar to what was observed in our S. mansoni study [24].
The probability of being cured for placebo-treated
children was particularly high in children with low egg
loads despite using a relatively strong diagnostic ap-
proach at baseline and follow-up by collecting per child
three consecutive urine samples for each time point
(baseline and follow-up). On the other hand, no cured
individual was observed in placebo-treated children
with heavy infection intensity at baseline. The high CR
observed in the placebo treatment arm among PSAC
was thus likely reflective of the low sensitivity of the
urine filtration method for light infections [40, 41]. Our
findings underscore the value of adding a placebo
group in Schistosoma drug efficacy trials—the overesti-
mation of CRs due to potential false negatives in light
infections is visible. More importantly, our observations
emphasise the need for Schistosoma species-related
standard operating procedures including reliable diag-
nostic tools, suitable for drug efficacy assessment for
low infection intensities [40–42].
With regard to safety outcomes, the main adverse
events observed in both PSAC and SAC are in line with
the adverse events reported in previous studies [16, 24,
34]. We observed an increase of adverse events severity
that was proportional to praziquantel dose in SAC, while
only one child showed moderate diarrhoea at the
60 mg/kg treatment dose in PSAC. However, as men-
tioned earlier, the accuracy of the adverse event severity
assessment in PSAC is questionable, in particular for
the less visible mild adverse events, since the reporting
is done by the children’s mothers.
Conclusions
Praziquantel showed a high response rate in PSAC and
SAC infected with S. haematobium, with high efficacy
observed already at 20 mg/kg, particularly in light infec-
tions. No benefit was observed using higher praziquantel
doses in the current study. However, to be able to pro-
vide ultimate dosing recommendations of praziquantel
for PSAC, additional studies might be required to sup-
port our conclusions, including pharmacokinetic studies
and studies in PSAC suffering from moderate and heavy
S. haematobium infections.
Additional file
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